DAWN — Day One Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.22bn
- $1.78bn
- $158.18m
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP-Dow, Oracle, Shopify
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Day One Biopharma jumps after Servier announces $2.5 billion acquisition
NASDAQ RESUMED AT 09:00 AM
Brief: Day One Biopharmaceuticals Inc Co To Pay Servier Pharmaceuticals Termination Fee Of $87.7 Million If Deal Is Terminated Under Certain Circumstances
Servier to buy Day One Biopharmaceuticals for $2.5 billion (updated)
Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion
Brief: Servier And Day One Biopharmaceuticals Announce Acquisition To Expand Servier’S Rare Oncology Portfolio
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:25 AM
Brief: EMA Recommends Granting Conditional Marketing Authorisation In EU For Ojemda
Day One Biopharmaceuticals full-year 2025 OJEMDA revenue rises
U.S. RESEARCH ROUNDUP-Cencora, Kennametal, Regeneron Pharmaceuticals
Brief: Day One Says OJEMDA 2026 U.S. Net Product Revenue Projected To Be $225 - $250 Million
Brief: Day One Completes Acquisition Of Mersana Therapeutics
Nasdaq biotech index hits record high, set to gain nearly 5% this week
Brief: Day One Biopharmaceuticals to Acquire Mersana Therapeutics
Day One Biopharmaceuticals Q3 revenue beats estimates on OJEMDA strength